CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...
BMO Capital Markets analyst Daniel Jester reiterated the Market Perform rating on Vertex, Inc. (NASDAQ:VERX), raising the price target to $28 from $24. Investors rewarded the consistent execution ...
Vertex Pharmaceuticals Incorporated (VRTX) is a good speculative biotech play to look into. That's because it is doing well in the Cystic Fibrosis [CF] space. It will still continue to do well with ...
StockStory.org on MSN
Reflecting on therapeutics stocks’ Q3 earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...
Vertex Solutions, an IT and Technology recruiter established since 1997, have undertaken a process of change to establish and communicate three clear and distinct divisions of their business Vertex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results